Immatics, a leading company in the field of cancer immunotherapy, today announced the completion of its Series E financing, raising $58 million.
Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies
Immatics Initiates the First Phase I Clinical Trial of its Unique ACTengine®
Immatics, a leading company in the field of cancer immunotherapy, today announced that it has initiated enrollment of patients into a phase I trial of IMA201, its first T-cell Receptor (TCR)-transduced adoptive cell therapy program.
Allecra Announces Initiation of a Phase 2 Clinical Trial for its Novel Antibiotic to Treat Resistant Bacterial Infections
Allecra’s novel b-lactamase inhibitor AAI101, co-administered with the powerful b-lactam cefepime, is to be evaluated in patients for its potential to combat hospital-acquired, resistant Gram-negative infections